Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high-grade metastatic tumor with rhabdoid and focal neuroendocrine features 2020
2019 Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived XenograftsScientific Reports.  9. 2019
2019 Corruption of neuroblastoma patient derived xenografts with human T cell lymphomaJournal of Pediatric Surgery.  54:2117-2119. 2019
2019 A unique phenotype of T-cell acute lymphoblastic leukemia in a patient with GATA2 haploinsufficiency 2019
2019 The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survivalJournal of Pediatric Surgery.  54:1206-1213. 2019
2019 Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in HepatoblastomaTranslational Oncology.  12:200-208. 2019
2019 The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumorOncotarget.  10:5534-5548. 2019
2018 Quality Initiative to Improve time to Antibiotics for Febrile Pediatric Patients with Potential Neutropenia.Pediatric Quality and Safety.  3:e095. 2018
2018 Targeting PIM kinase as a therapeutic strategy in human hepatoblastomaOncotarget.  9:22665-22679. 2018
2018 Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report.Neuro-Oncology.  20:132-142. 2018
2018 Adolescent and young adult oncology, version 2.2018: Clinical practice guidelines in oncology 2018
2017 Benefit Finding and Quality of Life in Caregivers of Childhood Cancer SurvivorsCancer Nursing.  40:E28-E37. 2017
2017 Inferior outcomes for black children with high risk acute lymphoblastic leukemia and the impact of socioeconomic variables 2017
2017 Demographic, medical, and psychosocial predictors of benefit finding among caregivers of childhood cancer survivors 2017
2015 Predictors of colorectal cancer surveillance among survivors of childhood cancer treated with radiation: A report from the Childhood Cancer Survivor StudyCancer.  121:1856-1863. 2015
2014 Barriers to the Use of Psychosocial Support Services Among Adolescent and Young Adult Survivors of Pediatric Cancer.Journal of Adolescent and Young Adult Oncology.  3:112-116. 2014
2014 Adolescent and young adult oncology, version 2.2014. 2014
2014 Adolescent and young adult oncology, version 2.2014: Featured updates to the NCCN guidelines 2014
2014 Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors.Fertility and Sterility.  101:227-231. 2014
2013 Cognitive influences as mediators of family and peer support for pediatric cancer survivors' physical activity 2013
2012 Adolescent and young adult oncology clinical practice guidelines in oncology 2012
2012 Toward a safer cure for low-risk Hodgkin lymphoma in children 2012
2012 Social, demographic, and medical influences on physical activity in child and adolescent cancer survivorsJournal of Pediatric Psychology.  37:198-208. 2012
2011 Auditory complications in childhood cancer survivors: A report from the childhood cancer survivor study 2011
2010 Ocular late effects in childhood and adolescent cancer survivors: A report from the childhood cancer survivor study 2010
2009 Predictors of inactive lifestyle among adult survivors of childhood cancerCancer.  115:1984-1994. 2009
2006 Visual complications in childhood cancer survivors: A Childhood Cancer Survivor Study report.Journal of Clinical Oncology.  24:9006. 2006

Chapter

Year Title Altmetric
2018 Epidemiology of Childhood Cancer.  1-20. 2018

Investigator On

  • A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ALTE11C2 Study - Health Effects after Antracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ALTE11C2 Study – Health Effects After Antracycline and Radiation Therapy (HEART) – Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • APEC1621SC - PEDIATRIC MATCH PCR - COG FOUNDATION  awarded by CHILDREN'S ONCOLOGY GROUP
  • Adaptive Immunity and Persistent SARS-CoV-2 Replication  awarded by National Cancer Institute/NIH/DHHS
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CCOP Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase ll Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia  awarded by Duke University
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • MCC 18613 Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • NIH COG Phase I Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee
  • PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by EISAI, INC.
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP
  • Reduced Burden Of Oncology Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents, and Young Adults with CD20+ Mature B-Cell Lymphoma  awarded by NEW YORK MEDICAL COLLEGE
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Transforming Pediatric Oncology Healthcare Through Family Navigation  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • Teaching Activities

  • 52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020) 2020
  • 52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020) 2020
  • 52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020) 2020
  • 52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020) 2020
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020) 2020
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2020) 2020
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2019) 2019
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2019) 2019
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2017) 2017
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2016) 2016
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2015) 2015
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2015) 2015
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2014) 2014
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2013) 2013
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2011) 2011
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2010) 2010
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2009) 2009
  • PCL2225 - HEMATOLOGY / ONCOLOGY (Fall Term 2008) 2008
  • Education And Training

  • Vanderbilt University Medical Center, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, University of South Carolina System : Columbia 2000
  • Full Name

  • Kimberly Whelan